![](https://investorshub.advfn.com/uicon/158678.png?cb=1661594561)
Friday, January 04, 2019 8:57:50 AM
There are enough details provided to at least support the notion that the investors have a firm belief that the market for the Galera drug is adequate to justify their investment and that it will be approved. The $70M in equity won't provide a return unless Galera goes public. The $80M in debt won't be paid back unless and until the drug is approved and marketed. Single digit royalties will require sales of over $800M to pay back that debt (and the "multiple" term suggests that they expect more).
"The financing includes a $70 million equity raise and an $80 million royalty financing payable from future sales. Per the terms of the royalty purchase agreement, Clarus will receive single-digit future commercial royalties from the sales of GC4419 and a related pipeline asset until the total royalty amount achieves an undisclosed multiple of the initial $80 million, upon which the royalty terminates."
They put up $150M and it's all at risk. I'm not sure if knowing that should "help investors value our bom drug" in a positive way or otherwise. We've heard opinions here suggesting that a simple swish and spit should easily trump an intravenous alternative and the common sense logic of that is undeniable, but the Galera investors appear not to be afraid of it.
I'd like to read the deal but as a private company we're stuck with the details in the PR.
But can it core A apple?
Yes Ralph, of course it can core A apple.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM